vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and YELP INC (YELP). Click either name above to swap in a different company.
YELP INC is the larger business by last-quarter revenue ($360.0M vs $247.1M, roughly 1.5× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 10.5%, a 0.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -0.5%). YELP INC produced more free cash flow last quarter ($72.3M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 4.0%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Yelp Inc. is an American company that develops the Yelp.com website and the Yelp mobile app, which publishes crowd-sourced reviews about businesses. It also operates Yelp Guest Manager, a table reservation service. It is headquartered in San Francisco.
ANIP vs YELP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $360.0M |
| Net Profit | $27.5M | $37.8M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 13.6% |
| Net Margin | 11.1% | 10.5% |
| Revenue YoY | 29.6% | -0.5% |
| Net Profit YoY | 367.5% | -10.5% |
| EPS (diluted) | $1.14 | $0.60 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $360.0M | ||
| Q3 25 | $227.8M | $376.0M | ||
| Q2 25 | $211.4M | $370.4M | ||
| Q1 25 | $197.1M | $358.5M | ||
| Q4 24 | $190.6M | $362.0M | ||
| Q3 24 | $148.3M | $360.3M | ||
| Q2 24 | $138.0M | $357.0M | ||
| Q1 24 | $137.4M | $332.8M |
| Q4 25 | $27.5M | $37.8M | ||
| Q3 25 | $26.6M | $39.3M | ||
| Q2 25 | $8.5M | $44.1M | ||
| Q1 25 | $15.7M | $24.4M | ||
| Q4 24 | $-10.3M | $42.2M | ||
| Q3 24 | $-24.2M | $38.4M | ||
| Q2 24 | $-2.3M | $38.0M | ||
| Q1 24 | $18.2M | $14.2M |
| Q4 25 | 14.1% | 13.6% | ||
| Q3 25 | 15.9% | 14.1% | ||
| Q2 25 | 6.6% | 14.4% | ||
| Q1 25 | 13.3% | 8.2% | ||
| Q4 24 | -2.3% | 14.8% | ||
| Q3 24 | -13.8% | 12.9% | ||
| Q2 24 | 3.7% | 11.1% | ||
| Q1 24 | 14.8% | 3.4% |
| Q4 25 | 11.1% | 10.5% | ||
| Q3 25 | 11.7% | 10.5% | ||
| Q2 25 | 4.0% | 11.9% | ||
| Q1 25 | 8.0% | 6.8% | ||
| Q4 24 | -5.4% | 11.7% | ||
| Q3 24 | -16.3% | 10.7% | ||
| Q2 24 | -1.7% | 10.7% | ||
| Q1 24 | 13.2% | 4.3% |
| Q4 25 | $1.14 | $0.60 | ||
| Q3 25 | $1.13 | $0.61 | ||
| Q2 25 | $0.36 | $0.67 | ||
| Q1 25 | $0.69 | $0.36 | ||
| Q4 24 | $-0.45 | $0.58 | ||
| Q3 24 | $-1.27 | $0.56 | ||
| Q2 24 | $-0.14 | $0.54 | ||
| Q1 24 | $0.82 | $0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $319.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $710.9M |
| Total Assets | $1.4B | $958.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $319.4M | ||
| Q3 25 | $262.6M | $333.6M | ||
| Q2 25 | $217.8M | $301.1M | ||
| Q1 25 | $149.8M | $324.4M | ||
| Q4 24 | $144.9M | $317.9M | ||
| Q3 24 | $145.0M | $397.0M | ||
| Q2 24 | $240.1M | $384.8M | ||
| Q1 24 | $228.6M | $420.8M |
| Q4 25 | $540.7M | $710.9M | ||
| Q3 25 | $505.8M | $733.2M | ||
| Q2 25 | $436.8M | $746.4M | ||
| Q1 25 | $418.6M | $728.0M | ||
| Q4 24 | $403.7M | $744.0M | ||
| Q3 24 | $405.9M | $739.5M | ||
| Q2 24 | $455.8M | $735.3M | ||
| Q1 24 | $452.0M | $722.0M |
| Q4 25 | $1.4B | $958.5M | ||
| Q3 25 | $1.4B | $989.9M | ||
| Q2 25 | $1.3B | $980.2M | ||
| Q1 25 | $1.3B | $985.2M | ||
| Q4 24 | $1.3B | $983.6M | ||
| Q3 24 | $1.3B | $980.2M | ||
| Q2 24 | $920.8M | $965.0M | ||
| Q1 24 | $914.5M | $993.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $84.5M |
| Free Cash FlowOCF − Capex | $29.1M | $72.3M |
| FCF MarginFCF / Revenue | 11.8% | 20.1% |
| Capex IntensityCapex / Revenue | 0.5% | 3.4% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.24× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $323.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $84.5M | ||
| Q3 25 | $44.1M | $131.5M | ||
| Q2 25 | $75.8M | $58.0M | ||
| Q1 25 | $35.0M | $98.0M | ||
| Q4 24 | $15.9M | $71.0M | ||
| Q3 24 | $12.5M | $102.3M | ||
| Q2 24 | $17.4M | $39.7M | ||
| Q1 24 | $18.3M | $72.9M |
| Q4 25 | $29.1M | $72.3M | ||
| Q3 25 | $38.0M | $118.9M | ||
| Q2 25 | $71.8M | $45.0M | ||
| Q1 25 | $32.5M | $87.5M | ||
| Q4 24 | $13.5M | $60.0M | ||
| Q3 24 | $7.7M | $92.5M | ||
| Q2 24 | $13.0M | $30.1M | ||
| Q1 24 | $13.7M | $65.9M |
| Q4 25 | 11.8% | 20.1% | ||
| Q3 25 | 16.7% | 31.6% | ||
| Q2 25 | 34.0% | 12.2% | ||
| Q1 25 | 16.5% | 24.4% | ||
| Q4 24 | 7.1% | 16.6% | ||
| Q3 24 | 5.2% | 25.7% | ||
| Q2 24 | 9.4% | 8.4% | ||
| Q1 24 | 10.0% | 19.8% |
| Q4 25 | 0.5% | 3.4% | ||
| Q3 25 | 2.7% | 3.3% | ||
| Q2 25 | 1.9% | 3.5% | ||
| Q1 25 | 1.3% | 2.9% | ||
| Q4 24 | 1.3% | 3.0% | ||
| Q3 24 | 3.2% | 2.7% | ||
| Q2 24 | 3.2% | 2.7% | ||
| Q1 24 | 3.3% | 2.1% |
| Q4 25 | 1.10× | 2.24× | ||
| Q3 25 | 1.66× | 3.34× | ||
| Q2 25 | 8.87× | 1.32× | ||
| Q1 25 | 2.23× | 4.02× | ||
| Q4 24 | — | 1.68× | ||
| Q3 24 | — | 2.66× | ||
| Q2 24 | — | 1.04× | ||
| Q1 24 | 1.00× | 5.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
YELP
| Advertising Services | $231.4M | 64% |
| Advertising Restaurants And Other | $106.8M | 30% |
| Other Revenue | $21.8M | 6% |
